AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

AstraZeneca said work on its new plant north of Charlottesville will begin immediately and be open within five years.

NHS patients risk losing access to the world’s best medicines unless the UK spends more on developing new treatments, the ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney ...

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

AstraZeneca stock bounded into a buy zone Thursday after sales of its cancer drugs beat Wall Street's expectations by about 5 ...

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

Future weight loss drugs will also be made available at $149 a month. Other drugs made by the two companies will also be offered at the lower, most-favored-nations price for Medicaid and Trump Rx.

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.

Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...